IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The ...
Investor's Business Daily on MSN
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of ...
After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.
The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...
In earlier laboratory experiments, researchers had observed that mRNA vaccines improve the effectiveness of cancer drugs such ...
Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback